Literature DB >> 24726846

K+ channels as potential targets for the treatment of gastrointestinal motor disorders.

Diego Currò1.   

Abstract

K(+) channels play important functional roles in excitable cells, as neurons and muscle cells. The activation or inhibition of K(+) channels hyperpolarizes or depolarizes the cell membrane, respectively. These effects determine in the smooth muscle decrease or increase in Ca(2+) influx through voltage-gated Ca(2+) (CaV1.2) channels and relaxation or contraction, respectively. Recent studies highlight the importance of voltage-dependent type 7 K(+) (KV7 or KCNQ) channels in regulating muscle tone and contractility in stomach and colon. KV7 channels, that include 5 subtypes (KV7.1-7.5), are activated at relatively negative potential values, close to those of the resting membrane potential for the smooth muscle cells of some segments of the gastrointestinal tract. Thus, they contribute to set the resting membrane potential and their blockade induces increase in smooth muscle contractility in stomach and colon. In addition, KV7 channel activation produces profound relaxations of gastric and colonic smooth muscle. Therefore, KV7 channel activators could be used to relax the smooth muscle and relieve symptoms in diseases such as functional dyspepsia and irritable bowel syndrome with prevalent diarrhea. The discovery of activators selective for the channel subtypes present in the smooth muscle, mainly KV7.4 and 7.5, would allow avoiding adverse cardiac and nervous system effects. A further step forward would be characterizing putative differences among the KV7 channel subtypes expressed in the various smooth muscles and synthesizing molecules specific for the gastrointestinal smooth muscle.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  4-Aminopyridine (PubChem CID: 1727); Apamin (PubChem CID: 16218850); DMP-543 (PubChem CID: 9887884); E-4031 (PubChem CID: 3185); Flupirtine; Flupirtine (PubChem CID: 53276); Iberiotoxin (PubChem CID: 16132435); K(V)7 channels; KCNQ channels; Linopirdine (PubChem CID: 3932); Retigabine; Retigabine (PubChem CID: 121892); Tetraethylammonium (PubChem CID: 5413); XE-991 (PubChem CID: 656732)

Mesh:

Substances:

Year:  2014        PMID: 24726846     DOI: 10.1016/j.ejphar.2014.03.049

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  The signaling of amitriptyline-induced inhibitory effect on electrical field stimulation response in colon smooth muscle.

Authors:  Tin Sandar Zaw; Phyu Phyu Khin; Uy Dong Sohn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-28       Impact factor: 3.000

2.  KV7 channels in the human detrusor: channel modulator effects and gene and protein expression.

Authors:  Riccardo Bientinesi; Cesare Mancuso; Maria Martire; Pier Francesco Bassi; Emilio Sacco; Diego Currò
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-10-19       Impact factor: 3.000

3.  Activation of KCNQ channels located on the skeletal muscle membrane by retigabine and its influence on the maximal muscle force in rat muscle strips.

Authors:  P Zagorchev; E Apostolova; V Kokova; L Peychev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-01-27       Impact factor: 3.000

4.  Kv7 Channels and Excitability Disorders.

Authors:  Frederick Jones; Nikita Gamper; Haixia Gao
Journal:  Handb Exp Pharmacol       Date:  2021

5.  Adiponectin Decreases Gastric Smooth Muscle Cell Excitability in Mice.

Authors:  Eglantina Idrizaj; Rachele Garella; Giovanni Castellini; Fabio Francini; Valdo Ricca; Maria Caterina Baccari; Roberta Squecco
Journal:  Front Physiol       Date:  2019-08-06       Impact factor: 4.566

6.  Systems Pharmacology Dissection of Multi-Scale Mechanisms of Action of Huo-Xiang-Zheng-Qi Formula for the Treatment of Gastrointestinal Diseases.

Authors:  Miaoqing Zhao; Yangyang Chen; Chao Wang; Wei Xiao; Shusheng Chen; Shuwei Zhang; Ling Yang; Yan Li
Journal:  Front Pharmacol       Date:  2019-01-11       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.